301060 Stock Overview
Shanghai Labway Clinical Laboratory Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Shanghai Labway Clinical Laboratory Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.98 |
| 52 Week High | CN¥15.97 |
| 52 Week Low | CN¥7.34 |
| Beta | 0.62 |
| 11 Month Change | -8.94% |
| 3 Month Change | 19.09% |
| 1 Year Change | -34.73% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301060 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | -2.3% | -0.1% | -0.9% |
| 1Y | -34.7% | -13.3% | 5.4% |
Return vs Industry: 301060 underperformed the CN Healthcare industry which returned -13.3% over the past year.
Return vs Market: 301060 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 301060 volatility | |
|---|---|
| 301060 Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 8.6% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 301060 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301060's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,487 | Weixiong Zeng | www.labway.cn |
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of vitro diagnostic products. It sells vitro diagnostic instruments, reagents, and related accessories and consumables.
Shanghai Labway Clinical Laboratory Co., Ltd Fundamentals Summary
| 301060 fundamental statistics | |
|---|---|
| Market cap | CN¥3.98b |
| Earnings (TTM) | -CN¥181.30m |
| Revenue (TTM) | CN¥1.72b |
2.3x
P/S Ratio-22.0x
P/E RatioIs 301060 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301060 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.72b |
| Cost of Revenue | CN¥1.43b |
| Gross Profit | CN¥295.45m |
| Other Expenses | CN¥476.74m |
| Earnings | -CN¥181.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 17.13% |
| Net Profit Margin | -10.51% |
| Debt/Equity Ratio | 15.3% |
How did 301060 perform over the long term?
See historical performance and comparison